Vibostolimab coformulated with pembrolizumab versus pembrolizumab alone as adjuvant therapy for high-risk stage IIB–IV melanoma (KEYVIBE-010): a randomised, double-blind, phase 3 study
Authors
Christian Caglevic (ORCID: https://orcid.org/0000-0003-3319-1678)
Gareth Rivalland
Rodrigo U. Villarroel
Karmele Mujika
Zhiguo Luo
Sung Ho Park (ORCID: https://orcid.org/0000-0003-4856-7287)
Corlia Coetzee
Jason Luke
Omer Dizdar
Dirk Schadendorf
Gal Markel
Dmitri Grebennik
Clemens Krepler
Jun Guo
Piotr Rutkowski
Kevin Donovan
Paolo A Ascierto
Reinhard Dummer
Antoni Ribas
Matteo S Carlino
Axel Hauschild
Georgina V Long
Muhammad A Khattak
Jing Chen
Yu Chen
Institutions
Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
Fujian Medical University (CN)
Union Hospital (HK)
University of Auckland (NZ)
Yonsei University (KR)
Peking University (CN)
Royal North Shore Hospital (AU)
Rabin Medical Center (IL)
Hollywood Private Hospital (AU)
UCLA Medical Center (US)
Sydney Hospital (AU)
Fudan University Shanghai Cancer Center (CN)
Peking University Cancer Hospital (CN)
University Hospital of Zurich (CH)
Hospital São Vicente de Paulo (BR)
University Hospital Schleswig-Holstein (DE)
Hacettepe University Hospital (TR)
Hospital São Vicente (BR)
Melanoma Institute Australia (AU)
Essen University Hospital (DE)
Médecins Sans Frontières (ZA)
University of Pittsburgh Medical Center (US)
Fundación Arturo López Pérez (CL)
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
Onkologikoa (ES)
Ministry of Education (ET)
Fujian Provincial Cancer Hospital (CN)
The Maria Sklodowska-Curie National Research Institute of Oncology (PL)
West German Heart and Vascular Center Essen (DE)
Huazhong University of Science and Technology (CN)
Vibostolimab coformulated with pembrolizumab versus pembrolizumab alone as adjuvant therapy for high-risk stage IIB–IV melanoma (KEYVIBE-010): a randomised, double-blind, phase 3 study
Christian Caglevic, Gareth Rivalland, Rodrigo U. Villarroel, Karmele Mujika et al.
Journal
The Lancet Oncology
Topics
Cancer Immunotherapy and Biomarkers
article
Vibostolimab coformulated with pembrolizumab versus pembrolizumab alone as adjuvant therapy for high-risk stage IIB–IV melanoma (KEYVIBE-010): a randomised, double-blind, phase 3 study
Christian Caglevic, Gareth Rivalland, Rodrigo U. Villarroel, Karmele Mujika, Zhiguo Luo, Sung Ho Park, Corlia Coetzee, Jason Luke, Omer Dizdar, Dirk Schadendorf, Gal Markel, Dmitri Grebennik, Clemens Krepler, Jun Guo, Piotr Rutkowski, Kevin Donovan, Paolo A Ascierto, Reinhard Dummer, Antoni Ribas, Matteo S Carlino, Axel Hauschild, Georgina V Long, Muhammad A Khattak, Jing Chen, Yu Chen
article en
Abstract
No abstract available for this paper.
Publication Tag
The Lancet OncologyVol. 27(3)
Institutions
Merck & Co., Inc., Rahway, NJ, USA (United States) (US), Fujian Medical University (CN), Union Hospital (HK), University of Auckland (NZ), Yonsei University (KR), Peking University (CN), Royal North Shore Hospital (AU), Rabin Medical Center (IL), Hollywood Private Hospital (AU), UCLA Medical Center (US), Sydney Hospital (AU), Fudan University Shanghai Cancer Center (CN), Peking University Cancer Hospital (CN), University Hospital of Zurich (CH), Hospital São Vicente de Paulo (BR), University Hospital Schleswig-Holstein (DE), Hacettepe University Hospital (TR), Hospital São Vicente (BR), Melanoma Institute Australia (AU), Essen University Hospital (DE), Médecins Sans Frontières (ZA), University of Pittsburgh Medical Center (US), Fundación Arturo López Pérez (CL), Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT), Onkologikoa (ES), Ministry of Education (ET), Fujian Provincial Cancer Hospital (CN), The Maria Sklodowska-Curie National Research Institute of Oncology (PL), West German Heart and Vascular Center Essen (DE), Huazhong University of Science and Technology (CN), University of Lübeck (DE)